Research ArticleConference Proceedings
Drug Development for Asthma and COPD: A Regulatory Perspective
Marianne Mann and Robert J Meyer
Respiratory Care June 2018, 63 (6) 797-817; DOI: https://doi.org/10.4187/respcare.06009
Marianne Mann
Dr Mann is an independent clinical/regulatory drug development consultant in Highland, Maryland.
MDRobert J Meyer
Greenleaf Health, Washington, DC and the University of Virginia, Charlottesville, Virginia.
MDReferences
- 1.↵Pharmaceutical Research and Manufacturers of America. Biopharmaceutical research and development: the process behind new medicines. 2015. http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf Accessed December 27, 2017.
- 2.↵United States Food and Drug Administration. Guidances (drugs). https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm Accessed December 27, 2017.
- 3.↵United States Food and Drug Administration. Guidance for industry. Providing clinical evidence of effectiveness for human drug and biological products. May 1998. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072008.pdf Accessed December 27, 2017.
- 4.↵United States Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry. November 2016. https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf Accessed December 27, 2017.
- 5.↵United States Food and Drug Administration. Guidance for industry. Expedited programs for serious conditions – drugs and biologics. May 2014. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf Accessed December 27, 2017.
- 6.↵United States Food and Drug Administration. Novel drugs summary 2016. https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm534863.htm Accessed December 27, 2017.
- 7.↵
- Katial RK,
- Bensch GW,
- Busse WW,
- Chipps BE,
- Denson JL,
- Gerber AN,
- et al
- 8.↵
- Nordenberg T
- 9.↵United States Food and Drug Administration. Application no. 21-730 medical reviews. March 2005. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021730s000_MedR.pdf Accessed December 27, 2017.
- 10.↵
- Nelson H,
- Weiss ST,
- Bleeker ER,
- Yancey SW,
- Dorinsky PM
- 11.↵
- Mann M,
- Chowdhury B,
- Sullivan E,
- Nicklas R,
- Anthracite R,
- Meyer RJ
- 12.↵
- Chowdhury BA,
- Seymour SM,
- Levenson MS
- 13.↵
- 14.
- 15.
- 16.↵Merck. Press release announcing top line results from long-term LABA safety study of Dulera inhalation aerosol. May 22, 2017. http://www.mrknewsroom.com/news/company-statements/merck-announces-top-line-results-long-term-laba-safety-study-dulera-mometaso Accessed December 27, 2017.
- 17.↵Boehringer Ingelheim Pharmaceuticals. Spiriva Respimat full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207070s000lbl.pdf Accessed December 27, 2017.
- 18.↵
- Kerstjens HAM,
- Engel M,
- Dahl R,
- Paggiaro P,
- Beck E,
- Vandewalker M,
- et al
- 19.↵United States Food and Drug Administration. Approval NDA 207070/Original 1. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207070Orig1s000ltr.pdf Accessed December 27, 2017.
- 20.↵
- 21.↵
- Temple RJ,
- Meyer RJ
- 22.↵United States Food and Drug Administration. Guidance for industry. Orally inhaled and intranasal corticosteroids: evaluation of the effects on growth in children. March 2007. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071968.pdf Accessed December 27, 2017.
- 23.↵
- Marcello C,
- Carlo L
- 24.↵Merck. Singulair full prescribing information. June 2016. http://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf Accessed December 27, 2017.
- 25.↵
- 26.↵
- 27.↵
- Mitchell PD,
- El-Gammal AI,
- O'Byrne PM
- 28.↵
- Menzella F,
- Lusuardi M,
- Montanari G,
- Galeone C,
- Facciolongo N,
- Zucchi L
- 29.↵
- Nair P,
- Pizzichini MM,
- Kjarsgaard M,
- Inman MD,
- Efthimiadis A,
- Pizzichini E,
- et al
- 30.↵
- 31.↵
- Castro M,
- Zangrilli J,
- Weschler ME,
- Bateman ED,
- Grusselle GG,
- Bardin P,
- et al
- 32.↵
- Bagnasco D,
- Ferrando M,
- Varricchi G,
- Passalacqua G,
- Canonica GW
- 33.↵United States Food and Drug Administration. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidance for industry. May 2016. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071575.pdf Accessed December 27, 2017.
- 34.↵GlaxoSmithKline. Advair Diskus full prescribing information. February 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021077s058lbl.pdf Accessed December 27, 2017.
- 35.↵
- Casaburi R,
- Celli B,
- Crapo J,
- Criner G,
- Croxton T,
- Gaw A,
- et al
- 36.↵
- Mannino DM,
- Tal-Singer R,
- Lomas DA,
- Vestbo J,
- Barr G,
- Tetzlaff K,
- et al
- 37.↵
- Vestbo J,
- Anderson W,
- Coxson HO,
- Crim C,
- Dawber L,
- Edwards L,
- et al
- 38.↵United States Food and Drug Administration. Draft. Qualification of biomarker – plasma fibrinogen in studies examining exacerbations and/or all-cause mortality in patients with chronic obstructive pulmonary disease. http://www.fdanews.com/ext/resources/files/07-15/07-07-15-plasmafibrinogen.pdf?1486936442 Accessed December 27, 2017.
- 39.↵
- 40.↵
- Jones PW
- 41.
- Meguro M,
- Barley EA,
- Spencer S,
- Jones PW
- 42.↵
- Wijkstra PJ,
- TenVergert EM,
- Van Altena R,
- Otten V,
- Postma DS,
- Kraan J,
- Koeter GH
- 43.↵United States Food and Drug Administration. Clinical outcome assessment compendium. Version 1. December 2015. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM481225.pdf Accessed December 27, 2017.
- 44.↵Evidra. EXACT-PRO initiative. March 2016. http://www.exactproinitiative.com Accessed December 27, 2017.
- 45.↵United States Food and Drug Administration. Application no. 022383Orig1s000 summary review. July 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000SumR.pdf Accessed December 27, 2017.
- 46.↵
- Chowdhury BA,
- Seymour SM,
- Michele TM,
- Durmowicz AG,
- Liu D,
- Rosebraugh CJ
- 47.↵Food and Drug Administration. Approval packages for application no. 21-395/S029 Spiriva HandiHaler. December 2009. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021395Orig1s029.pdf Accessed December 27, 2017.
- 48.↵
- Singh S,
- Like YK,
- Furberg CD
- 49.↵
- Lee TA,
- Pickard AS,
- Au DH,
- Bartle B,
- Weiss KB
- 50.↵
- Tashkin DP,
- Celli B,
- Senn S,
- Burkhart D,
- Kesten S,
- Menjoge S,
- et al
- 51.↵
- Rodrigo GJ,
- Castro-Rodriguez JA,
- Nannini LJ,
- Plaza Moral V,
- Schiavi EA
- 52.↵
- Wise RA,
- Anzueto A,
- Cotton D,
- Dahl R,
- Devins T,
- Disse B,
- et al
- 53.↵
- Michele TM,
- Pinheiro S,
- Iyasu S
- 54.↵United States Food and Drug Administration. Application no. 202450Orig1s000 summary review. July 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000SumR.pdf Accessed December 27, 2017.
- 55.↵Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and exacerbations in moderate to very severe COPD patients (ASCENT COPD). https://clinicaltrials.gov/ct2/show/NCT01966107 Accessed December 27, 2017.
- 56.↵United States Food and Drug Administration. Application no. 207930Orig1s000 summary review. October 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000SumR.pdf Accessed December 27, 2017.
- 57.↵Novartis Pharmaceuticals. Utibron Neohaler full prescribing information. January 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207930s002lbl.pdf Accessed December 27, 2017.
- 58.↵United States Food and Drug Administration. Application no. 204275Orig1s000 medical reviews. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204275Orig1s000MedR.pdf Accessed December 27, 2017.
- 59.↵GlaxoSmithKline. GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations. September 2017. https://us.gsk.com/en-us/media/press-releases/2017/gsk-and-innoviva-report-positive-headline-results-from-impact-study-showing-single-inhaler-triple-therapy-trelegy-ellipta-reduced-copd-exacerbations/ Accessed December 27, 2017.
- 60.↵
- 61.↵United States Food and Drug Administration. Product-specific guidances for generic drug development. October 2017. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm Accessed December 27, 2017.
In this issue
Respiratory Care
Vol. 63, Issue 6
1 Jun 2018
Drug Development for Asthma and COPD: A Regulatory Perspective
Marianne Mann, Robert J Meyer
Respiratory Care Jun 2018, 63 (6) 797-817; DOI: 10.4187/respcare.06009